Labcorp Investor Day: 5-8% revenue CAGR through 2029, reaffirms 2026 guidance

LABCORP HOLDINGS INC.

Reaffirms 2026 guidance: revenue $14.71-14.83B (5.4-6.3% growth), adjusted EPS $18.10-18.55, FCF $1.24-1.36B.
Long-term outlook through 2029: 5-8% compound annual revenue growth, 8.5-11.5% adjusted EPS CAGR.
Targets 75-150 bps adjusted operating margin expansion by end of 2029; FCF growth in line with adjusted earnings.
Strategic priorities: specialty testing (oncology, neurology, autoimmune, women's health), health-system partnerships, AI/robotics.
CEO Adam Schechter cites above-market growth expectation; CFO Julia Wang details disciplined capital deployment framework.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.